Better Therapeutics, Inc. develops prescription digital therapeutics that delivers behavioral therapy, and creates feedback mechanisms using remotely monitored and patient-generated data. Its products include Nutritional Cognitive Behavioral Therapy (Nutritional CBT), behavioral therapy for patients with type 2 diabetes and other cardiometabolic diseases. It also manufactures therapeutic medicines, such as BTÂ001, BTÂ002, BTÂ003, BTÂ004, and BTÂ005 for cardiometabolic diseases. The company was incorporated in 2015 and is based in San Francisco, California.
IPO Year: 2021
Exchange: NASDAQ
Website: bettertx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/24/2021 | $17.00 | Buy | Chardan Capital Markets |
| 11/10/2021 | Outperform | Cowen |
One million prescriptions for AspyreRx will be offered to patients in underserved communities disproportionately affected by type 2 diabetes Better Therapeutics, Inc. (NASDAQ:BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced a major partnership with the American College of Lifestyle Medicine's (ACLM) National Training Initiative (NTI), aimed at improving diabetes outcomes in underserved communities across the United States. Through this partnership, Better Therapeutics is committed to making one million prescriptions of its U.S. Food and Drug Administration (FDA)-authorized product, AspyreRx, available to support
Industry Veteran Joins Health Technology Pioneer to Bring Prescription Digital Therapeutics for Type 2 Diabetes and other Cardiometabolic Conditions to Market Better Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases, announced today that Diane Gomez-Thinnes joined the company as Chief Commercial Officer starting October 26, 2022. Gomez-Thinnes brings more than two decades of experience in the healthcare industry, leading the commercialization and launch of products spanning the medical device, prescription medicines and consumer health sect
Better Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that Frank Karbe will join the company as President and Chief Executive Officer and serve as a member of the Board of Directors starting July 5th, 2022. Current CEO and company co-founder, Kevin Appelbaum, will continue to serve in that role until then. "I'm thrilled to welcome Frank to the Better Therapeutics team," said outgoing CEO Kevin Appelbaum. "Over the past seven years, I have had the privilege of assembling and leading an extraordinarily talented and committed t
Better Therapeutics, Inc. (("Better Therapeutics", NASDAQ:BTTX), a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced the appointment of Deepti Sodhi Jaggi, PharmD, as its Chief Strategy Officer. "Deepti has spent her career driving innovation at the intersection of healthcare and technology," said Kevin Appelbaum, co-founder and Chief Executive Officer. "She brings a unique mix of intelligence, curiosity and courage to not be constrained by precedent. I look forward to working closely with her to make our vision of transforming the treatment of cardiometabolic diseases a reality." Dr. J
Better Therapeutics, Inc. (("Better Therapeutics", NASDAQ:BTTX), a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced the appointment of Major General Elder Granger, M.D., U.S. Army (retired) to its board of directors. "Dr. Granger's track record of leadership in navigating complex policy, regulatory and competitive environments will be welcome additions to the Better Therapeutics board," said David Perry, co-founder and chairman of Better Therapeutics. "His extensive board experience coupled with an unwavering commitment to improving the delivery of healthcare will be invaluable as we wo
Better Therapeutics, Inc. (("Better Therapeutics", NASDAQ:BTTX), a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced the appointment of Thiago Licias de Oliveira as its Chief People Officer. In this newly created role, Thiago will develop and implement a people strategy to build, structure and retain an exceptional team through a period of anticipated high growth. Most recently, Thiago was the Head of Global Talent Management for Johnson & Johnson Medical Devices. "Thiago is a passionate leader who embraces the critical importance of people in enabling companies to succeed," said Kevin A
EFFECT - Better Therapeutics, Inc. (0001832415) (Filer)
EFFECT - Better Therapeutics, Inc. (0001832415) (Filer)
EFFECT - Better Therapeutics, Inc. (0001832415) (Filer)
EFFECT - Better Therapeutics, Inc. (0001832415) (Filer)
EFFECT - Better Therapeutics, Inc. (0001832415) (Filer)
POS AM - Better Therapeutics, Inc. (0001832415) (Filer)
POS AM - Better Therapeutics, Inc. (0001832415) (Filer)
POS AM - Better Therapeutics, Inc. (0001832415) (Filer)
POS AM - Better Therapeutics, Inc. (0001832415) (Filer)
POS AM - Better Therapeutics, Inc. (0001832415) (Filer)
Chardan Capital Markets initiated coverage of Better Therapeutics with a rating of Buy and set a new price target of $17.00
Cowen initiated coverage of Better Therapeutics with a rating of Outperform
SC 13G/A - Better Therapeutics, Inc. (0001832415) (Subject)
SC 13D/A - Better Therapeutics, Inc. (0001832415) (Subject)
SC 13D/A - Better Therapeutics, Inc. (0001832415) (Subject)
SC 13D/A - Better Therapeutics, Inc. (0001832415) (Subject)
SC 13G - Better Therapeutics, Inc. (0001832415) (Subject)
SC 13D/A - Better Therapeutics, Inc. (0001832415) (Subject)
SC 13G/A - Better Therapeutics, Inc. (0001832415) (Subject)
SC 13G/A - Better Therapeutics, Inc. (0001832415) (Subject)
SC 13G/A - Better Therapeutics, Inc. (0001832415) (Subject)
SC 13G/A - Better Therapeutics, Inc. (0001832415) (Subject)
ORLANDO, FL / ACCESSWIRE / March 1, 2024 / RedChip Companies will air interviews with Better Therapeutics, Inc. (NASDAQ:BTTX) and Biotricity, Inc. (NASDAQ:BTCY) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, March 2, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Better Therapeutics: https://www.redchip.com/assets/access/bttx_accessBiotricity: https://www.redchip.com/assets/access/btcy_accessFrank Karbe, CEO of Better Therapeutics, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update. Better Therape
Company obtained FDA authorization for AspyreRxTM to treat adults with type 2 diabetes and announced commercial launch Company to host a conference call and webcast today at 8:30 a.m. ET Better Therapeutics, Inc. (NASDAQ:BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today reported financial results for the third quarter 2023 and provided an update on progress towards achieving key corporate milestones. "We made tremendous progress in Q3, which included the FDA authorization of AspyreRx and the completion of the work required for a commercial launch in early October. AspyreRx offers healthcare providers a clinically proven, convenie
Better Therapeutics, Inc. (NASDAQ:BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today announced it will release its third quarter 2023 financial results before the market opens on Thursday, November 09, 2023. Management will host a conference call and webcast to provide a business update at 8:30 a.m. ET / 5:30 a.m. PT on Thursday, November 09, 2023. To access the conference call, please register at: https://register.vevent.com/register/BI7ccccb1e37c44102b4f5ce26d785604d. Upon registering, each participant will be provided with call details and access codes. All participants are encouraged to join 10 minutes prior to the start time. The
Obtained FDA Authorization for AspyreRxTM to treat adults with type 2 diabetes Established price and launch metrics in preparation for expected launch in Q4 Completed financing transactions totaling $12.5 million in net proceeds Company to host conference call and webcast today at 4:30pm ET Better Therapeutics, Inc. (NASDAQ:BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today reported financial results for the second quarter 2023 and provided an update on progress towards achieving key corporate milestones. "Obtaining FDA authorization for AspyreRx was a pivotal milestone for our company and a catalyst for strengthening our fina
Better Therapeutics, Inc. (NASDAQ:BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today announced it will release its second quarter 2023 financial results after the market closes on Wednesday, August 09, 2023. Management will host a conference call and webcast to provide a business update at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, August 09, 2023. To access the conference call, please register at: https://register.vevent.com/register/BI614fa4bfabc545808e507d9f77a536a6. Upon registering, each participant will be provided with call details and access codes. All participants are encouraged to join 10 minutes prior to the start time. The
First prescription digital behavioral therapeutic device delivering novel form of cognitive behavioral therapy via smartphone In a randomized controlled trial AspyreRx demonstrated clinically meaningful and statistically significant durable reductions in A1c Company to host conference call and webcast on July 11 at 8:30 a.m. ET Better Therapeutics, Inc. (NASDAQ:BTTX), a pioneer in developing software to treat cardiometabolic diseases, today announced that the Food and Drug Administration (FDA) authorized AspyreRx™ (formerly BT-001), a prescription-only digital therapeutic (PDT) treatment indicated to provide cognitive behavioral therapy to patients 18 years or older with type 2 diabet
On track for an FDA decision mid-year Announced restructuring to extend cash runway Completed private placement financing Company to host conference call and webcast today at 8:30 a.m. ET Better Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital therapeutics (PDT) company developing a clinically validated, software-based, novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases, today reported financial results for the first quarter 2023 and provided an update on progress toward achieving key corporate milestones. "We successfully navigated several challenges in the first quarter of this year, laying the foundations for long-ter
Better Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital therapeutics (PDT) company developing a clinically validated, software-based novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced it will release its first quarter 2023 financial results before the market opens on Thursday, May 11, 2023. Management will host a conference call and webcast to provide a business update at 8:30 a.m. ET / 5:30 a.m. PT on Thursday, May 11, 2023. To access the conference call, please register at: https://register.vevent.com/register/BI5d9690c447df48b2b930b971560acd4f. Upon registering, each participant will be provided with call details a
Better Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital therapeutics (PDT) company developing a clinically validated, software-based, novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases, today announced a private placement of 7,878,786 shares of the Company's common stock at a price of $0.825 per share, which was the closing price of the Company's common stock on the Nasdaq Capital Market on April 5, 2023, for gross proceeds of approximately $6.5 million, before deducting offering expenses payable by Better Therapeutics. There was strong participation in the financing from certain officers and directors of the Company. Better The
Advanced preparations for potential commercial launch of BT-001 in U.S. in mid-2023 Reported positive topline results from exploratory trial for fatty liver disease Announced restructuring and other cost saving actions to extend financial runway Company to host conference call and webcast today at 8:30 a.m. ET Better Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital therapeutics (PDT) company developing a clinically validated, software-based, novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases, today reported financial results for the fourth quarter and full year of 2022 and provided an update on progress toward achieving key co
Better Therapeutics, Inc. (NASDAQ:BTTX) (the "Company") announced today that the Company is terminating its employees and will explore strategic alternatives, including assignment for the benefit of creditors and/or a wind-down of the Company. This decision was made at a special meeting of the board of directors on Wednesday evening, March 13, 2024. Further, as previously disclosed, the Company's securities are subject to delisting from the Nasdaq Stock Market unless the Company presents a plan to regain compliance with Nasdaq's continued listing standards before the Nasdaq hearings panel. The Company has voluntarily requested a delisting of its securities and expects its securities to be d
One million prescriptions for AspyreRx will be offered to patients in underserved communities disproportionately affected by type 2 diabetes Better Therapeutics, Inc. (NASDAQ:BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced a major partnership with the American College of Lifestyle Medicine's (ACLM) National Training Initiative (NTI), aimed at improving diabetes outcomes in underserved communities across the United States. Through this partnership, Better Therapeutics is committed to making one million prescriptions of its U.S. Food and Drug Administration (FDA)-authorized product, AspyreRx, available to support
Company to host sponsored education session on Saturday, March 09, 2024; Expanding access to a high quality and effective lifestyle modification intervention Better Therapeutics, Inc. (NASDAQ:BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced the acceptance of a late-breaking abstract presenting 180-day outcomes data and its participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), to be held from March 6 to 9, 2024, in Florence, Italy. ATTD serves as a premier international forum showcasing cutting-edge advancements in diabetes care, bringing together clinicians
ORLANDO, FL / ACCESSWIRE / March 1, 2024 / RedChip Companies will air interviews with Better Therapeutics, Inc. (NASDAQ:BTTX) and Biotricity, Inc. (NASDAQ:BTCY) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, March 2, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Better Therapeutics: https://www.redchip.com/assets/access/bttx_accessBiotricity: https://www.redchip.com/assets/access/btcy_accessFrank Karbe, CEO of Better Therapeutics, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update. Better Therape
Signifies the FDA's recognition of the Company's novel Cognitive Behavioral Therapy as a potential treatment for metabolic dysfunction-associated steatohepatitis Opens an accelerated path towards a potential second indication Better Therapeutics, Inc. (NASDAQ:BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its novel Cognitive Behavioral Therapy (CBT) platform intended to treat adults with metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH. Breakthrough status is reserved for technologi
Agreement is an important step towards securing broad coverage Better Therapeutics Inc. (NASDAQ:BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced that it has entered into a rebate agreement with one of the nation's leading Pharmacy Benefit Managers (PBMs) negotiating on behalf of over 70 million lives in the US. The rebate agreement, effective January 1, 2024, applies to the PBM's commercial book of business and provides plan participants of the PBM the ability to add AspyreRx™ to their formularies with rebate eligibility. Better Therapeutics launched AspyreRx in October 2023, after receiving U.S. Food and Drug
Over a lifetime horizon AspyreRx plus standard of care (SoC) was estimated to be superior to SoC alone providing more life years and improvements in quality of life at a lower cost Study suggests that using AspyreRx can empower patients to better manage their diabetes, with the potential to reduce long-term complications Better Therapeutics Inc. (NASDAQ:BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced the publication of health economic data for its prescription-only digital behavioral treatment for type 2 diabetes (T2D), AspyreRx. The study, titled "Cost-Effectiveness Analysis of a Prescription Digital Therape
Better Therapeutics, Inc. (NASDAQ:BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced it has submitted a request to the U.S. Food and Drug Administration (FDA) for Breakthrough Device Designation for its novel PDT designed to treat metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NAFLD and NASH. MASLD affects an estimated 25%–30% of adults in the U.S., including approximately 70% of individuals with type 2 diabetes and up to 90% of those with obesity. The more advanced form of this disease, MASH, affects approximately 5%–11%
Savings Expected to Extend Cash Runway Sufficiently to Demonstrate Commercial Traction with AspyreRx in Type 2 Diabetes Better Therapeutics, Inc. (NASDAQ:BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today disclosed several initiatives aimed at extending the company's cash runway sufficiently to demonstrate commercial traction with its lead product, AspyreRx. The company launched AspyreRx in October of this year, after receiving U.S. Food and Drug Administration (FDA) authorization in July for the treatment of adults with type 2 diabetes. Better Therapeutics successfully negotiated an amendment to its debt facility with Hercul
Better Therapeutics is recognized for its novel cognitive behavioral therapy app, AspyreRx™, leading the way in the North American diabetes digital behavioral therapeutics industry Better Therapeutics, Inc. (NASDAQ:BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced it has been awarded Frost & Sullivan's prestigious 2023 Best Practices Technology Innovation Leadership Award in the North American diabetes digital behavioral therapeutics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231114156864/en/Better Therapeutics Receives 2023 Technology Innov
4 - Better Therapeutics, Inc. (0001832415) (Issuer)
4 - Better Therapeutics, Inc. (0001832415) (Issuer)
4 - Better Therapeutics, Inc. (0001832415) (Issuer)
4 - Better Therapeutics, Inc. (0001832415) (Issuer)
4 - Better Therapeutics, Inc. (0001832415) (Issuer)
4 - Better Therapeutics, Inc. (0001832415) (Issuer)
4 - Better Therapeutics, Inc. (0001832415) (Issuer)
4 - Better Therapeutics, Inc. (0001832415) (Issuer)
4 - Better Therapeutics, Inc. (0001832415) (Issuer)
4 - Better Therapeutics, Inc. (0001832415) (Issuer)